Scleromyxedema

This is a type of Scleroderma where the skin looks thick and bumpy, like cobblestones. It's caused by extra cells and fluid building up in the skin, usually without thyroid problems.

Condition

What people with Scleromyxedema report

Every report comes from a Lived member, sent anonymously.

Have you tried IVIG for Scleromyxedema?

NameHow it went

About Scleromyxedema

What It Is

Scleromyxedema is a rare, long-lasting disease in which the skin becomes thickened and firm and is covered with many small, waxy bumps. The bumps are usually 2 to 3 millimeters across, often line up in rows and can merge into plaques on the face, neck, trunk, arms and legs, while the skin around them hardens. Over time this can thicken the skin between the eyebrows and over the ears, giving the face a heavy, furrowed look, and can make it hard to open the mouth fully or bend the fingers, and cause itching or uncomfortable skin sensations. The skin changes come from mucin, a gel-like substance that normally helps the skin hold water, building up in the deeper layer of the skin along with extra fibrous tissue. Scleromyxedema is not only a skin disease, though. Most people with it have an abnormal antibody in the blood, and roughly 70% develop problems in other organs, such as the muscles, esophagus, lungs, heart or nervous system. That is why it is treated as a serious whole-body condition rather than a cosmetic one. The names lichen myxedematosus and papular mucinosis cover a wider family of related disorders. Scleromyxedema is the generalized form. Localized forms produce similar bumps in a limited area without the abnormal antibody or organ involvement and usually follow a much milder course. Scleromyxedema can also look like scleroderma, but it is a different disease.

Causes & Risk Factors

The cause of scleromyxedema is not known. The leading explanation is that substances circulating in the blood, including signaling proteins called cytokines, drive skin cells called fibroblasts to multiply and overproduce mucin. In laboratory studies, blood serum from people with the condition stimulates these cells. Most people with scleromyxedema have a monoclonal gammopathy. This means a small group of antibody-making plasma cells, which live in the bone marrow, produces large amounts of one identical abnormal antibody, most often a type called IgG lambda. Doctors now group scleromyxedema with other conditions in which such a cell group causes harm through its effects on the body even when it is not a cancer. How the abnormal antibody leads to skin and organ changes is still unclear, and its level in the blood does not match how severe the disease is. Scleromyxedema usually begins in middle-aged adults, most often in their 40s and 50s, and affects men and women about equally. No lifestyle habit, infection or other trigger has been shown to cause it or to set off flares.

How It's Diagnosed

Diagnosis rests on three findings together. A skin biopsy, in which a small piece of skin is removed and examined under a microscope with stains that show mucin, reveals the typical combination of mucin deposits, extra fibroblasts and fibrous tissue. Blood tests called serum protein electrophoresis and immunofixation look for the abnormal antibody and identify its type. Thyroid tests rule out myxedema from an underactive thyroid, which can thicken the skin in a similar way. Classic criteria require that thyroid disease be absent, although some specialists argue the diagnosis can still be made when a thyroid problem exists alongside otherwise typical findings. Because scleromyxedema can affect other organs, the assessment also looks beyond the skin, guided by symptoms. This may include an echocardiogram (an ultrasound of the heart) and tests of the lungs, swallowing, muscles or nerves. A hematologist, a specialist in blood disorders, usually evaluates the abnormal antibody, including whether it comes from multiple myeloma, a cancer of plasma cells. Since the condition is rare and resembles other skin diseases, it is often diagnosed or confirmed by a dermatologist with experience in it.

Treatment Options

There are no formal treatment guidelines, because the disease is so rare that evidence comes mostly from case reports and small series rather than controlled trials. Treatment still matters: without it the disease tends to progress, and the aims are to soften the skin, restore movement and control involvement of other organs. High-dose intravenous immunoglobulin (IVIG) is the usual first treatment. IVIG is a concentrated antibody product made from donated human blood, given through a vein, typically over 2 to 5 days every 4 weeks. Nearly all reported patients improve at least partly, often in both the skin and internal organs, and younger people seem to respond especially well. The trade-offs are that IVIG does not lower the abnormal antibody, most people need to keep receiving infusions to stay in remission, and it is expensive and sometimes in short supply. When IVIG alone is not enough, it is often combined with corticosteroids (steroid medicines that calm inflammation) or with thalidomide (Thalomid), an immune-modifying medicine. For severe disease, relapses or serious complications, specialists may add treatments used for multiple myeloma that target the plasma cells making the abnormal antibody, such as lenalidomide (Revlimid), bortezomib with dexamethasone, or daratumumab, an antibody drug that targets plasma cells. In rare refractory cases, high-dose chemotherapy with an autologous stem cell transplant, using the person's own stem cells, has been used. In a small series, adding plasma cell treatment to IVIG produced deep and lasting responses and allowed some people to stop IVIG. Thalidomide and lenalidomide can cause severe birth defects, so they are available only through restricted programs that require strict pregnancy prevention. Thalidomide can also damage nerves, causing numbness or tingling, which sometimes limits its use. An older chemotherapy approach with melphalan was largely abandoned because it was linked to blood cancers and serious infections.

What to Expect

Scleromyxedema is usually a chronic condition with an unpredictable course. Published case series describe a guarded outlook, with some deaths from internal complications, related blood cancers or the effects of treatment. At the same time, many people improve substantially with IVIG, and softer skin can bring back movement in the face and hands. Relapse is common when treatment is reduced, so most people stay on long-term therapy with regular visits. Daily life is shaped by the skin and by any organ involvement. Tight skin can make it harder to open the mouth, grip objects or bend the fingers, and itching can be persistent. Some people have trouble swallowing, weakness in the muscles of the hips and shoulders, joint pain, numbness or tingling in the hands from carpal tunnel syndrome, or shortness of breath. IVIG means recurring infusion days, which can affect work and travel plans. Follow-up usually involves both a dermatologist and a hematologist. Regular blood tests track the abnormal antibody, partly because in up to about 10% of people the underlying plasma cell disorder progresses to multiple myeloma.

When to Seek Help

See a dermatologist if many small, firm, waxy bumps appear along with thickening or tightening of the skin, especially on the face, hands and arms. An early diagnosis allows treatment to start before the disease progresses. If you have scleromyxedema, contact your care team promptly about new or worsening trouble swallowing, muscle weakness, shortness of breath, numbness or tingling, or skin that starts tightening again between treatments, since these can signal organ involvement or relapse. A rare but life-threatening complication called dermato-neuro syndrome typically begins with a flu-like illness and fever and then affects the brain. Call 911 for a seizure, new confusion or unusual drowsiness in someone with scleromyxedema, especially after a fever.

Questions to Ask Your Doctor

  1. 1.How did you confirm that this is scleromyxedema rather than a localized form of papular mucinosis or scleroderma?
  2. 2.Which of my organs should be checked, and how often will we repeat those tests?
  3. 3.What results can I realistically expect from IVIG, and how will we decide whether to add or change treatment?
  4. 4.How will you monitor the abnormal antibody, and what changes would suggest it is turning into multiple myeloma?
  5. 5.Should my care involve a center or specialists with experience treating this disease?

Last reviewed • Oct 2026

Educational content, not medical advice.